US4749576A
(en)
*
|
1984-05-10 |
1988-06-07 |
Ciba-Geigy Corporation |
Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
|
JPS61218517A
(ja)
*
|
1985-03-25 |
1986-09-29 |
Bio Materiaru Yunibaasu:Kk |
経皮吸収製剤
|
FR2585246A1
(fr)
*
|
1985-07-26 |
1987-01-30 |
Cortial |
Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
|
US4794002A
(en)
*
|
1985-11-01 |
1988-12-27 |
Monsanto Company |
Modified polymeric surfaces and process for preparing same
|
JPH0643851B2
(ja)
*
|
1986-03-13 |
1994-06-08 |
大同メタル工業株式会社 |
軸受ユニット
|
US4983400A
(en)
*
|
1986-06-16 |
1991-01-08 |
Merck & Co., Inc. |
Controlled release combination of carbidopa/levodopa
|
US4780236A
(en)
*
|
1986-06-20 |
1988-10-25 |
Kiwi Brands, Inc. |
Lavoratory cleansing block containing polyethylene gycol disteatrate, guar gum and sodium chloride
|
US4743248A
(en)
*
|
1986-08-11 |
1988-05-10 |
Alza Corporation |
Dosage form for delivering acid sensitive beneficial agent
|
GB8620845D0
(en)
*
|
1986-08-28 |
1986-10-08 |
Reckitt & Colmann Prod Ltd |
Treatment of textile surfaces
|
US5219575A
(en)
*
|
1987-06-26 |
1993-06-15 |
Duphar International Research B.V. |
Compositions with controlled zero-order delivery rate and method of preparing these compositions
|
EP0297650A1
(fr)
*
|
1987-06-26 |
1989-01-04 |
Duphar International Research B.V |
Compositions avec une délivrance contrôlée d'ordre zéro et méthode pour leur préparation
|
US4910015A
(en)
*
|
1987-10-19 |
1990-03-20 |
Massachusetts Institute Of Technology |
Surface-active polysiloxanes and drug releasing materials thereof
|
GB8801863D0
(en)
*
|
1988-01-28 |
1988-02-24 |
Fulmer Yarsley Ltd |
Pharmaceutical formulations with controlled drug release
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
DE69603577T2
(de)
|
1995-02-10 |
1999-11-25 |
Medtronic, Inc. |
Verfahren und vorrichtung zur verabreichung von analgetika
|
US5945125A
(en)
*
|
1995-02-28 |
1999-08-31 |
Temple University |
Controlled release tablet
|
US20030203036A1
(en)
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
GB9703673D0
(en)
*
|
1997-02-21 |
1997-04-09 |
Bradford Particle Design Ltd |
Method and apparatus for the formation of particles
|
US6039968A
(en)
*
|
1997-06-24 |
2000-03-21 |
Hoechst Marion Roussel |
Intravaginal drug delivery device
|
DE19843904A1
(de)
*
|
1998-09-24 |
2000-03-30 |
Basf Ag |
Feste Dosierungsform mit polymerem Bindemittel
|
DE19843903A1
(de)
*
|
1998-09-24 |
2000-03-30 |
Basf Ag |
Feste Dosierungsform mit copolymerem Bindemittel
|
US6706283B1
(en)
*
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
US7943162B2
(en)
*
|
1999-10-21 |
2011-05-17 |
Alcon, Inc. |
Drug delivery device
|
CN1402632A
(zh)
|
1999-12-23 |
2003-03-12 |
辉瑞产品公司 |
水凝胶驱动的药物剂型
|
US20030086972A1
(en)
*
|
2000-08-09 |
2003-05-08 |
Appel Leah E. |
Hydrogel-driven drug dosage form
|
GB0027357D0
(en)
*
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
PT1409065E
(pt)
|
2001-07-23 |
2007-03-30 |
Alcon Inc |
Dispositivo de administração de fármacos oftálmicos
|
PT1385452E
(pt)
*
|
2001-07-23 |
2006-12-29 |
Alcon Inc |
Dispositivo de administração de fármacos oftálmicos
|
CA2464653C
(fr)
*
|
2001-10-29 |
2011-10-18 |
Therics, Inc. |
Systeme d'elaboration de formes pharmaceutiques a liberation controlee, du type forme pharmaceutique a profil de liberation d'ordre zero elaboree en impression tridimensionnelle
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
GB0310636D0
(en)
*
|
2003-05-08 |
2003-06-11 |
Nektar Therapeutics Uk Ltd |
Particulate materials
|
CA2524773C
(fr)
|
2003-05-08 |
2014-04-08 |
Nektar Therapeutics Uk Ltd |
Coformulations particulaires de substances actives comprenant des excipients
|
CN1805719A
(zh)
*
|
2003-07-10 |
2006-07-19 |
爱尔康公司 |
眼药输送装置
|
US20060246109A1
(en)
*
|
2005-04-29 |
2006-11-02 |
Hossainy Syed F |
Concentration gradient profiles for control of agent release rates from polymer matrices
|
US8153162B2
(en)
|
2005-09-27 |
2012-04-10 |
Tissuetech, Inc. |
Purified amniotic membrane compositions and methods of use
|
US8187639B2
(en)
*
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
EP1959966B1
(fr)
|
2005-11-28 |
2020-06-03 |
Marinus Pharmaceuticals, Inc. |
Formes galéniques de ganaxolone et procédés de preparation et d'utilisation de celles-ci
|
US8246973B2
(en)
|
2006-06-21 |
2012-08-21 |
Advanced Cardiovascular Systems, Inc. |
Freeze-thaw method for modifying stent coating
|
US10208158B2
(en)
|
2006-07-10 |
2019-02-19 |
Medipacs, Inc. |
Super elastic epoxy hydrogel
|
WO2008021368A2
(fr)
|
2006-08-11 |
2008-02-21 |
The Johns Hopkins University |
Compositions et méthodes de neuroprotection
|
EP2532235A1
(fr)
|
2006-09-22 |
2012-12-12 |
Pharmacyclics, Inc. |
Inhibiteurs de la tyrosine kinase de bruton
|
JP5411141B2
(ja)
|
2007-09-10 |
2014-02-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
WO2009073734A2
(fr)
|
2007-12-03 |
2009-06-11 |
Medipacs, Inc. |
Dispositif de mesure de fluide
|
WO2010027875A2
(fr)
|
2008-08-27 |
2010-03-11 |
Calcimedica Inc. |
Composés qui modulent le calcium intracellulaire
|
ES2559029T3
(es)
|
2009-04-24 |
2016-02-10 |
Tissue Tech, Inc. |
Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas
|
WO2011032011A1
(fr)
|
2009-09-10 |
2011-03-17 |
Medipacs, Inc. |
Actionneur à faible encombrement et méthode améliorée d'administration d'agents thérapeutiques commandée par le soignant
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
US9500186B2
(en)
|
2010-02-01 |
2016-11-22 |
Medipacs, Inc. |
High surface area polymer actuator with gas mitigating components
|
ES2602475T3
(es)
|
2010-04-15 |
2017-02-21 |
Tracon Pharmaceuticals, Inc. |
Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
|
PL2563776T3
(pl)
|
2010-04-27 |
2017-01-31 |
Calcimedica Inc |
Związki, które modulują wewnątrzkomórkowy wapń
|
US8754219B2
(en)
|
2010-04-27 |
2014-06-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CA3240281A1
(fr)
|
2010-06-03 |
2011-12-08 |
Pharmacyclics Llc |
Utilisation d'inhibiteurs de la tyrosine-kinase de bruton dans le traitement du lymphome folliculaire
|
CN103180316A
(zh)
|
2010-08-27 |
2013-06-26 |
钙医学公司 |
调节细胞内钙的化合物
|
US8668675B2
(en)
|
2010-11-03 |
2014-03-11 |
Flugen, Inc. |
Wearable drug delivery device having spring drive and sliding actuation mechanism
|
US9808030B2
(en)
|
2011-02-11 |
2017-11-07 |
Grain Processing Corporation |
Salt composition
|
US9526770B2
(en)
|
2011-04-28 |
2016-12-27 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
WO2012170905A1
(fr)
|
2011-06-10 |
2012-12-13 |
Tissuetech, Inc. |
Procédés de traitement de tissus fœtaux de support, produits en poudre à base de tissu fœtal de support et leurs utilisations
|
MX365393B
(es)
|
2011-09-13 |
2019-05-31 |
Pharmacyclics Llc |
Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas.
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
CN107982266B
(zh)
|
2012-01-06 |
2021-07-30 |
H.隆德贝克有限公司 |
氨基甲酸酯化合物及其制备和使用方法
|
CN104302689A
(zh)
|
2012-03-14 |
2015-01-21 |
麦德医像公司 |
含有过量活性分子的智能聚合物材料
|
CN104736178A
(zh)
|
2012-06-04 |
2015-06-24 |
药品循环公司 |
布鲁顿酪氨酸激酶抑制剂的晶形
|
CA2878163A1
(fr)
|
2012-07-11 |
2014-01-16 |
Tissuetech, Inc. |
Compositions contenant des complexes hc-ah/ptx3 et procedes d'utilisation associes
|
DK2900674T3
(en)
|
2012-09-28 |
2017-07-03 |
Univ Washington Through Its Center For Commercialization |
RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
JP6345786B2
(ja)
|
2013-12-05 |
2018-06-20 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼの阻害剤
|
WO2015164213A1
(fr)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
Réaction de ligature bio-orthogonale rapide et efficace et hétérocycles contenant du bore utiles en association avec celle-ci
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
US9775978B2
(en)
|
2014-07-25 |
2017-10-03 |
Warsaw Orthopedic, Inc. |
Drug delivery device and methods having a retaining member
|
US9764122B2
(en)
|
2014-07-25 |
2017-09-19 |
Warsaw Orthopedic, Inc. |
Drug delivery device and methods having an occluding member
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
CA2974395C
(fr)
|
2015-02-06 |
2023-08-22 |
University Of Washington |
Composes et procedes pour prevenir ou traiter la mort de cellules capillaires sensorielles
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
US20160243288A1
(en)
|
2015-02-23 |
2016-08-25 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
CA2977521C
(fr)
|
2015-02-27 |
2024-03-19 |
Curtana Pharmaceuticals, Inc. |
Composes d'uree 1-(aryle)-3-(heteroaryle) et utilisation comme inhibiteurs du facteur olig2
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of proton tyrosine kinase inhibitor
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
CN113413387A
(zh)
|
2015-05-11 |
2021-09-21 |
H.隆德贝克有限公司 |
治疗炎症或神经性疼痛的方法
|
JP2018516869A
(ja)
|
2015-05-20 |
2018-06-28 |
ティッシュテック,インク. |
上皮細胞の増殖および上皮間葉転換を防ぐための組成物および方法
|
CN108135904A
(zh)
|
2015-08-31 |
2018-06-08 |
药品循环有限责任公司 |
用于治疗多发性骨髓瘤的btk抑制剂组合
|
US10076650B2
(en)
|
2015-11-23 |
2018-09-18 |
Warsaw Orthopedic, Inc. |
Enhanced stylet for drug depot injector
|
WO2017100861A1
(fr)
|
2015-12-16 |
2017-06-22 |
The Walter And Eliza Hall Institute Of Medical Research |
Inhibition de protéines sh2 induites par des cytokines dans des cellules nk
|
WO2017125424A1
(fr)
|
2016-01-19 |
2017-07-27 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprenant un inhibiteur de btk
|
CN108472259A
(zh)
|
2016-01-19 |
2018-08-31 |
詹森药业有限公司 |
包含btk抑制剂的配制品/组合物
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
WO2017176652A2
(fr)
|
2016-04-04 |
2017-10-12 |
Sinopia Biosciences, Inc. |
Traitement de syndrome extrapyramidal à l'aide de trapidil
|
EP3463576A4
(fr)
|
2016-05-25 |
2020-01-15 |
Concentric Analgesics, Inc. |
Promédicaments à base d'agonistes de trpv1 phénoliques en association avec des anesthésiques locaux et des vasoconstricteurs pour améliorer une anesthésie locale
|
WO2017205766A1
(fr)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibiteurs de la kinase associée au récepteur de l'interleukine-1
|
WO2017205762A1
(fr)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibiteurs de la kinase associée au récepteur de l'interleukine 1
|
WO2017205769A1
(fr)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibiteurs de la kinase associée au récepteur de l'interleukine 1
|
USD802755S1
(en)
|
2016-06-23 |
2017-11-14 |
Warsaw Orthopedic, Inc. |
Drug pellet cartridge
|
US11090702B2
(en)
*
|
2016-06-28 |
2021-08-17 |
Trustees Of Tufts College |
Compositions and methods for delivery of active agents
|
CA3030821A1
(fr)
|
2016-07-18 |
2018-01-25 |
Arthrosi Therapeutics, Inc. |
Composes, compositions et methodes de traitement ou de prevention d'un symptome associe a la goutte ou a l'hyperuricemie
|
AU2017314842B9
(en)
|
2016-08-26 |
2022-02-10 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
US10434261B2
(en)
|
2016-11-08 |
2019-10-08 |
Warsaw Orthopedic, Inc. |
Drug pellet delivery system and method
|
MA46866B1
(fr)
|
2016-11-16 |
2021-11-30 |
H Lundbeck As |
Une forme cristalline d'un inhibiteur de magl
|
AU2017361254B2
(en)
|
2016-11-16 |
2021-09-23 |
H. Lundbeck A/S. |
Pharmaceutical formulations
|
WO2019046731A1
(fr)
|
2017-09-01 |
2019-03-07 |
University Of Washington |
Formes cristallines de composés pour prévenir ou traiter la mort de cellules ciliées sensorielles
|
WO2019169112A1
(fr)
|
2018-02-28 |
2019-09-06 |
Curtana Pharmaceuticals, Inc. |
Inhibition de l'activité d'olig2
|
JP2021532183A
(ja)
|
2018-07-27 |
2021-11-25 |
コンセントリック アナルジェジクス,インク. |
フェノール性trpv1アゴニストのpeg化プロドラッグ
|
KR20210117261A
(ko)
|
2018-12-31 |
2021-09-28 |
바이오메아 퓨전, 인크. |
메닌-mll 상호작용의 비가역적 억제제
|
CA3133093A1
(fr)
|
2019-03-15 |
2020-09-24 |
Unicycive Therapeutics, Inc. |
Derives de nicorandil
|
CN115427403A
(zh)
|
2020-04-21 |
2022-12-02 |
H.隆德贝克有限公司 |
单酰基甘油脂肪酶抑制剂的合成
|
WO2022133064A1
(fr)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Composés de pyrimidine fusionnée utilisés comme inhibiteurs de l'interaction ménine-mll
|
WO2022150525A1
(fr)
|
2021-01-06 |
2022-07-14 |
Awakn Life Sciences |
Mdma dans le traitement d'un trouble de consommation d'alcool
|
CA3218884A1
(fr)
|
2021-05-11 |
2022-11-17 |
David Nutt |
Composes et compositions therapeutiques a base d'aminoindane
|
EP4346788A2
(fr)
|
2021-06-03 |
2024-04-10 |
Arcadia Medicine, Inc. |
Compositions entactogènes énantiomères et leurs méthodes d'utilisation
|
AU2022325861A1
(en)
|
2021-08-11 |
2024-02-29 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
AU2022331496A1
(en)
|
2021-08-20 |
2024-02-29 |
Biomea Fusion, Inc. |
Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
|
WO2023028091A1
(fr)
|
2021-08-23 |
2023-03-02 |
Alexander Shulgin Research Institute |
Empathogènes deutérés
|
WO2023027966A1
(fr)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Composés de pyrazine en tant qu'inhibiteurs irréversibles de flt3
|
WO2023039240A1
(fr)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
Inhibitors irréversibles de kras
|
WO2023086341A1
(fr)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibiteurs de kras
|
TW202340177A
(zh)
|
2021-12-30 |
2023-10-16 |
美商拜歐米富士恩股份有限公司 |
作為 flt3抑制劑之吡嗪化合物
|
WO2023139163A1
(fr)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
Esters de 1,3-benzodioxole et leur utilisation thérapeutique
|
WO2023156565A1
(fr)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Composes cycliques pontés et leur utilisation thérapeutique comme agents du snc
|
WO2023235618A1
(fr)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Composés de pyrimidine fusionnés en tant qu'inhibiteurs de la ménine
|
WO2024011142A1
(fr)
|
2022-07-06 |
2024-01-11 |
Oppilan Pharma Limited |
Formes cristallines d'un modulateur du récepteur s1p
|
WO2024155719A1
(fr)
|
2023-01-18 |
2024-07-25 |
Biomea Fusion, Inc. |
Formes cristallines de n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phényl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-pipéridinyl]méthyl]-2- pyridinecarboxamide en tant qu'inhibiteur covalent de l'interaction ménine-mll
|